Darlene Dobkowski, MA

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Radiotherapy with standard of care for the treatment of patients with low-burden metastatic prostate cancer had minimal effects on quality of life over a five-year follow-up period.

Adding the investigational cancer drug lanraplenib to Xospata, if found to be effective, may broaden treatment options for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.

In less than a year, Christine Whelchel went from receiving a diagnosis of breast cancer to becoming a trailblazing “Jeopardy!” champion.

Care teams often implant a chemo port into patients with cancer to provide easy access for blood draws and to deliver treatments such as chemotherapy and antibiotics. Here, as part of its Heal at Home series, CURE® works with a nurse to provide a guide for patients to care for their port.

One patient turned her diagnosis of multiple myeloma into a way to educate others as an advocate.

Experts from Cancer Treatment Centers of America explain why mental health is important from cancer diagnosis through survivorship, the types of therapy and more.

The results, according to the study authors, may highlight a bigger issue related to structural racism in health care.

Patients with stage 3 colon cancer who consume processed meat or unprocessed red meat after receiving their diagnosis may not be at an increased risk for cancer recurrence or death.

Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.

The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

Certain patients with metastatic breast cancer may benefit from Enhertu compared with standard of care with Kadcyla despite higher rates of side effects including lung inflammation and interstitial lung disease.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.

Tiragolumab plus Tecentriq and chemotherapy did not significantly improve progression-free survival and overall survival in patients with extensive-stage small-cell lung cancer.

Twenty years of updates in technology, techniques and available medications has provided more hope for patients with colorectal cancer, with more advances on the horizon.

AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

One patient with stage 4 kidney cancer pivoted from being a journalist to a patient advocate, educating patients and others about a cancer that requires more awareness and research funding.

As The DONNA Foundation’s 15th annual marathon brings the breast cancer community together, two “streakers” discuss why they continue to participate in every marathon.

As more and more people in their 20s and 30s begin to receive diagnoses of multiple myeloma, a type of blood cancer, one expert stresses that continued research to improve survival in this patient population is critical.

A patient’s experience with polycythemia vera — a rare blood cancer — led to her becoming an advocate for others to help ease all the nerves and uncertainty that many patients face when they hear they have cancer.

Drugs that control blood pressure and lower cholesterol, among others, may help patients derive greater benefit from cancer treatment, but study findings have left researchers reassessing their next moves.